Ivacaftor · Kalydeco
Small molecule
Evidence outlook
Approved: Cystic Fibrosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Cystic fibrosis with gating or R117H CFTR mutations (monotherapy) and in combination regimens
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
STRIVE NCT00909532 · Cystic Fibrosis The study was randomized and quadruple-blinded, compared ivacaftor with placebo, and enrolled 167 participants; its objective primary endpoint, percent-predicted FEV1, was met with a statistically significant treatment difference. However, the supplied registry record does not report a power or sample-size calculation, so the trial receives a moderate grade despite its otherwise strong design. Registry: NCT00909532 | 3 | Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks) 2010-07 | Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | Partial signal | link ↗ |
View 1 more trial
ENVISION NCT00909727 · Cystic Fibrosis The trial was randomized, quadruple-blinded, and placebo-controlled, with 26 participants in each arm, and its primary endpoint was the objective clinical measure FEV1. The primary endpoint was met, but no power calculation is reported in the provided sources, so the evidence is limited despite the strong trial design and statistically significant result. Registry: NCT00909727 | 3 | Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks) 2010-11 | Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Used as active comparator (6)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Studied as part of a combination product (44)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 3 (22)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Appears in other studies (3)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
5 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Cystic Fibrosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ivacaftor (Kalydeco): this drug | Approved | Small molecule | CFTR | Partial signal | NCT00909727: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo 0.1 percent of predicted volume (L) (Standard Error 2.1) | 150 mg Ivacaftor q12h 12.6 percent of predicted volume (L) (Standard Error 2.1) NCT00909532: Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24 (baseline through 24 weeks): Placebo -0.2 percent of predicted volume (L) (Standard Error 0.7) | 150 mg Ivacaftor q12h 10.4 percent of predicted volume (L) (Standard Error 0.7) | |
| Elexacaftor / Tezacaftor / Ivacaftor (Trikafta) | Approved | Small molecule | CFTR, CFTR | Reliable signal | NCT03525444: Absolute change in ppFEV1 from baseline at Week 4 (interim analysis, 403 patients): treatment difference vs placebo 13.8 percentage points (95% CI 12.1 to 15.4), P<0.0001; CT.gov LS means +13.6 vs -0.2 (TRIKAFTA label section 14.1; CT.gov posted results). NCT03525548: Absolute change in ppFEV1 from baseline at Week 4 vs tezacaftor/ivacaftor: +10.4 vs +0.4; treatment difference 10.0 percentage points (95% CI 7.4 to 12.6), P<0.0001 (TRIKAFTA label section 14.1; CT.gov posted results). | |
| Lumacaftor (Orkambi) | Approved | Small molecule | CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| Tezacaftor / Ivacaftor (Symdeko) | Approved | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) | Approved | Small molecule | CFTR, CFTR | Reliable signal | No reviewed efficacy summary in this indication | |
| KB407 | Phase 1 | Gene therapy / editing | CFTR (gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| VX-828 | Phase 1 | Small molecule | CFTR | not yet graded | No reviewed efficacy summary in this indication | |
| Luvomeran | Discontinued | RNA / oligonucleotide | CFTR (mRNA replacement) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Kalydeco (Ivacaftor) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.